Phase 2/3 Study Evaluating Efficacy and Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA)Versus Reference L-asparaginase Treatment in Combination With Standard Polychemotherapy in Patient With First Recurrence of Philadelphia Negative Acute Lymphoblastic Leukemia

Trial Profile

Phase 2/3 Study Evaluating Efficacy and Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA)Versus Reference L-asparaginase Treatment in Combination With Standard Polychemotherapy in Patient With First Recurrence of Philadelphia Negative Acute Lymphoblastic Leukemia

Completed
Phase of Trial: Phase II/III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs ERY-ASP (Primary) ; Asparaginase
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GRASPALL; GRASPIVOTALL
  • Sponsors ERYtech Pharma
  • Most Recent Events

    • 10 Oct 2017 According to an ERYtech Pharma media release, based on the data from this trial the company has resubmitted to the European Medicine Agency (EMA) its Marketing Authorization Application (MAA) for eryaspase (GRASPA) for the treatment of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). The MAA resubmission also include additional data to address the outstanding questions of the Committee for Medicinal Products for Human Use (CHMP) of the EMA.
    • 14 Nov 2016 According to an ERYtech Pharma media release, Company announces withdrawal of European MAA as it received received Day 180 List of Outstanding Issues (LOI) in Sep 2016 from CHMP's to provide the requested additional data regarding the comparability between the old and new form of asparaginase encapsulated in GRASPA, also the Company intends to resubmit the MAA mid-2017.
    • 10 May 2016 According to an ERYtech Pharma media release, the Marketing Authorization Application (MAA) for GRASPA to treat patients with relapsed and refractory (Acute-lymphoblastic-leukaemia) ALL, submitted in September 2015, is currently under review by the EMA's Commission for Human Medicinal Products (CHMP).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top